GlassScriptPhysician profile
Steven Bruce Lefkowitz
NPI 1801235148
$2,589.42
in general payments reported to CMS, 2019-2025
35 companies · $509 in 2025
The $509 reported for 2025 was more than what 81% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $169 · 2020: $216 · 2021: $259 · 2022: $492 · 2023: $466 · 2024: $479 · 2025: $509.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,454.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,453.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $285.51 | 2020-2023 | |
| Astellas Pharma US INC | $205.97 | 2022-2025 | Veozah |
| Pfizer INC. | $185.22 | 2021-2025 | |
| Exeltis, USA INC. | $182.90 | 2021-2025 | Slynd |
| Novo Nordisk INC | $178.40 | 2022-2025 | Wegovy, Saxenda |
| Coopersurgical, INC. | $138.67 | 2019-2025 | Endosee |
| Hologic Sales and Service, LLC | $134.29 | 2020-2025 | Coolseal Generator, Fluent Fluid Management System |
| Sumitomo Pharma America, INC. | $130.23 | 2023-2025 | Myfembree |
| Axonics, INC. | $116.24 | 2024 | Bulkamid, Axonics |
| Sage Therapeutics, LLC | $108.01 | 2024-2025 | Zurzuvae |
| Mayne Pharma Commercial LLC | $107.22 | 2021-2024 | |
| Therapeuticsmd, INC. | $97.61 | 2019-2021 | |
| Daiichi Sankyo INC. | $89.77 | 2019-2025 | Injectafer |
| Evofem Biosciences, INC. | $74.31 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $65.26 | 2019-2023 | Gardasil 9 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $62.81 | 2021-2022 | |
| Currax Pharmaceuticals LLC | $43.58 | 2020-2024 | Contrave |
| Myovant Sciences INC. | $41.42 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $39.23 | 2019-2022 | |
| Ascend Therapeutics US, LLC | $32.51 | 2021-2022 | |
| Medartis INC. | $28.41 | 2022 | |
| Scynexis, INC. | $23.90 | 2022 | |
| Channel Medsystems, INC. | $23.83 | 2025 | |
| Supernus Pharmaceuticals, INC. | $22.83 | 2025 | Qelbree |
| Exact Sciences Corporation | $21.08 | 2025 | Cologuard Collection Kit |
| Lilly USA, LLC | $19.38 | 2024 | Zepbound |
| Aspira Women'S Health INC | $17.24 | 2019 | |
| Ethicon US, LLC | $16.83 | 2024 | Enseal, Vistaseal, Surgicel Nu-Knit |
| Pacira Pharmaceuticals Incorporated | $16.34 | 2023 | Exparel |
| Mycovia Pharmaceuticals, INC. | $15.45 | 2023 | Vivjoa |
| Mission Pharmacal Company | $15.31 | 2020 | |
| Millicent US INC | $14.43 | 2025 | Femlyv |
| Allergan, INC. | $12.87 | 2020 | |
| Duchesnay USA Incorporated | $11.77 | 2019 | |
| Acessa Health INC. | $10.59 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Lefkowitz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.